Pionner in plant biotechnology, GREENTECH develops and produces for cosmetic, pharmaceutical and nutraceutical fields high tech active ingredients from plants, marine and microbial worlds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

news image

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

news image

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More

CELL AND GENE THERAPY

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

news image

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More
news image

RESEARCH

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More
news image

GLAXOSMITHKLINE TEAMS WITH VIR BIOTECHNOLOGY TO DEVELOP CORONAVIRUS VACCINE, TREATMENTS

The Business Journals | April 06, 2020

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vi...

Read More
news image

CELL AND GENE THERAPY

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More
news image

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More